Goldman Sachs
ELVN icon

Goldman Sachs’s Enliven Therapeutics ELVN Stock Holding History

Goldman Sachs’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Sell
322,156
-150,959
-32% -$6.41M ﹤0.01% 2828
2026
Q1 		$18.5M Buy
473,115
+235,911
+99% +$6.54M ﹤0.01% 2503
2025
Q4 		$3.65M Sell
237,204
-25,068
-10% -$499K ﹤0.01% 4043
2025
Q3 		$5.37M Buy
262,272
+72,767
+38% +$1.47M ﹤0.01% 3569
2025
Q2 		$3.8M Sell
189,505
-22,247
-11% -$421K ﹤0.01% 3672
2025
Q1 		$4.17M Buy
211,752
+80,506
+61% +$1.73M ﹤0.01% 3536
2024
Q4 		$2.95M Buy
131,246
+9,461
+8% +$245K ﹤0.01% 3958
2024
Q3 		$3.11M Buy
121,785
+56,032
+85% +$1.3M ﹤0.01% 3761
2024
Q2 		$1.54M Buy
65,753
+48,480
+281% +$1.02M ﹤0.01% 4132
2024
Q1 		$304K Sell
17,273
-5,425
-24% -$83.2K ﹤0.01% 4967
2023
Q4 		$314K Buy
22,698
+5,008
+28% +$61.3K ﹤0.01% 4981
2023
Q3 		$242K Sell
17,690
-9,596
-35% -$162K ﹤0.01% 4975
2023
Q2 		$557K Sell
27,286
-14,125
-34% -$285K ﹤0.01% 4685
2023
Q1 		$907K Buy
+41,411
New +$842K ﹤0.01% 4442
2022
Q3 		– Sell
-218,145
Closed -$1.06M – 6332
2022
Q2 		$1.06M Buy
218,145
+9,751
+5% +$47.7K ﹤0.01% 4564
2022
Q1 		$1.57M Sell
208,394
-2,543
-1% -$16.8K ﹤0.01% 4442
2021
Q4 		$1.9M Buy
210,937
+201,446
+2,122% +$2.64M ﹤0.01% 4295
2021
Q3 		$155K Buy
9,491
+6,854
+260% +$142K ﹤0.01% 5811
2021
Q2 		$83K Sell
2,637
-549
-17% -$17K ﹤0.01% 5982
2021
Q1 		$108K Buy
+3,186
New +$162K ﹤0.01% 5825
2020
Q2 		– Sell
-12,000
Closed -$769K – 5261
2020
Q1 		$769K Buy
+12,000
New +$765K ﹤0.01% 3936

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Goldman Sachs's ELVN Position: Q2 2026 in Review

Goldman Sachs reduced its Enliven Therapeutics (ELVN) stake by 32% in Q2 2026, selling an estimated $6.41M and leaving 322,156 shares worth $16.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2828.

Goldman Sachs first reported a position in ELVN in Q1 2020 and has held it in 21 quarters since. The position peaked at $18.5M in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Goldman Sachs held 322,156 shares of Enliven Therapeutics worth $16.3M as of Q2 2026.
  • Goldman Sachs sold 150,959 Enliven Therapeutics shares in Q2 2026, an estimated $6.41M.
  • Enliven Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2828 holding.
  • Goldman Sachs first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • Goldman Sachs's Enliven Therapeutics position peaked at $18.5M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.